Aptinyx (NASDAQ:APTX) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, March 21st. Analysts expect the company to announce earnings of ($0.50) per share for the quarter.
APTX opened at $4.06 on Friday. Aptinyx has a 1-year low of $4.04 and a 1-year high of $32.25.
APTX has been the subject of several research analyst reports. Leerink Swann dropped their target price on shares of Aptinyx from $35.00 to $22.00 and set an “outperform” rating for the company in a research report on Thursday, January 17th. Cantor Fitzgerald reissued a “buy” rating and issued a $40.00 target price on shares of Aptinyx in a research report on Monday, December 3rd. JPMorgan Chase & Co. downgraded shares of Aptinyx from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $30.00 to $8.00 in a research report on Thursday, January 17th. Zacks Investment Research raised shares of Aptinyx from a “hold” rating to a “buy” rating and set a $6.00 target price for the company in a research report on Monday, January 21st. Finally, BMO Capital Markets decreased their price target on shares of Aptinyx to $18.00 and set an “outperform” rating for the company in a report on Friday, January 18th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Aptinyx presently has an average rating of “Buy” and a consensus target price of $18.80.
A hedge fund recently raised its stake in Aptinyx stock. Geode Capital Management LLC raised its position in shares of Aptinyx Inc (NASDAQ:APTX) by 20.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 107,464 shares of the company’s stock after purchasing an additional 17,914 shares during the period. Geode Capital Management LLC owned 0.32% of Aptinyx worth $1,777,000 at the end of the most recent quarter. 63.11% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was posted by Markets Daily and is the property of of Markets Daily. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.themarketsdaily.com/2019/03/15/aptinyx-aptx-set-to-announce-quarterly-earnings-on-thursday.html.
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
Read More: Balance Sheet
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.